Gilead Sciences, Assembly Biosciences Have Announced 12-Year Partnership For Antiviral Therapies, With An Initial Focus On Assembly Bio's Herpesviruses, Hepatitis B Virus, And Hepatitis D Virus; Assembly Bio To Receive $100M Upfront Payment
Gilead Sciences, Assembly Biosciences Have Announced 12-Year Partnership For Antiviral Therapies, With An Initial Focus On Assembly Bio's Herpesviruses, Hepatitis B Virus, And Hepatitis D Virus; Assembly Bio To Receive $100M Upfront Payment
吉利德科学和Assembly Biosciences宣布了为期12年的抗病毒疗法合作伙伴关系，最初的重点是Assembly Bio的疱疹病毒、乙型肝炎病毒和丁型肝炎病毒；Assembly Bio将获得1亿美元的预付款
Gilead Sciences, Assembly Biosciences Have Announced 12-Year Partnership For Antiviral Therapies, With An Initial Focus On Assembly Bio's Herpesviruses, Hepatitis B Virus, And Hepatitis D Virus; Assembly Bio To Receive $100M Upfront Payment
吉利德科学公司、Assembly Biosciences公司宣布了为期12年的抗病毒治疗合作伙伴关系，最初的重点是Assembly Bio公司的疱疹病毒、乙肝病毒和丁型肝炎病毒；Assembly Bio公司将获得1亿美元的预付款